PhaseBio finds $46m in initial public…

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

Raremark makes $3.9m impression

Cass Entrepreneurship Fund has returned to back a $3.9m funding round for Raremark, which is working on delivering precision medicine for patients suffering from rare diseases.

Qpex tackles $33m series A

Qpex has raised $33m in series A funding from Stanford University Draper Fund after spinning out of the Medicines Company to develop drugs targeting superbugs.


GCV Synergize 2018
2nd November 2018
Venture Houston 2018
8th November 2018
GCVI Summit 2019
30th January 2019
Tarhan to retire from UCLB
Cengiz Tarhan will step down from his role as managing director of UCL Business at the end of this month, 25 years after he established tech transfer office.
CuraSen lures Johnson & Johnson to series A
Johnson & Johnson was among the investors in a $54.5m series A round for CuraSen Therapeutics, which is commercialising research from Stanford University.
Big deal: Novartis picks up Endocyte for $2.1bn
Endocyte emerged out of Purdue University in 1996, completed an initial public offering in 2011 and has now agreed to an acquisition by Novartis worth $2.1bn.
News roundup 22 October 2018
A round up of all the latest news on for our subscribers.
RapidAim hits funding target
The Csiro Innovation Fund has invested $890,000 in RapidAim, co-founded by three Csiro researchers, to support a trial of a fruit fly monitoring system.
Washington credits fintech incubator
University of Washington’s CoMotion has formed a fintech incubator with nonprofit credit union Becu called the Becu Fintech Incubator.
test reg


Not yet subscribed?

See your subscription offers here